USE OF POSITRON EMISSION TOMOGRAPHY TO EVALUATE THE EFFECTIVENESS OF CHEMOTHERAPY IN PATIENTS WITH HEAD AND NECK-CANCER

被引:0
|
作者
SEIFERT, E
SCHADEL, A
HABERKORN, U
STRAUSS, LG
机构
关键词
D O I
暂无
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Positron emission tomography (PET) demonstrates the qualitative and quantitative characteristics of multiple metabolic pathways. In a prospective study we evaluated the metabolism of glucose in the tumors of ten patients suffering from head and neck cancer before and after chemotherapy with cisplatin and 5-fluorouracil. Using 18-fluorodeoxyglucose (FDG), it was possible to show changes in tumor metabolism after chemotherapy. In general, chemotherapy reduced the volume of the primary tumor and the lymph nodes. There was a linear relation between the changes in metabolism and growth rate, but in a few patients the lymph nodes and the primary tumor showed a different metabolic reaction. With FDG metabolism and PET we were able to determine the response rate of the tumor in vivo before chemotherapy.
引用
收藏
页码:90 / 93
页数:4
相关论文
共 50 条
  • [31] Positron emission tomography and stage migration for head and neck cancer
    VanderWalde, Noam Avraham
    Salloum, Ramzi George
    Liu, Tsai-Ling
    Hornbrook, Mark Christopher
    O'Keeffe-Rosetti, Maureen Cecelia
    Ritzwoller, Debra Pearson
    Fishman, Paul Arthur
    Lafata, Jennifer Elston
    Khandani, Amir H.
    Chera, Bhishamjit S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] SURGICAL COMPLICATIONS IN PATIENTS WITH HEAD AND NECK-CANCER RECEIVING CHEMOTHERAPY
    COREY, JP
    CALDARELLI, DD
    HUTCHINSON, JC
    HOLINGER, LD
    TAYLOR, SG
    SHOWEL, JL
    KOOSER, JA
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1986, 112 (04) : 437 - 439
  • [33] COMBINATION CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH ADVANCED HEAD AND NECK-CANCER
    AIGINGER, P
    HOLLMANN, K
    KUHBOCK, J
    MAILATH, G
    POTZI, P
    BLUT, 1983, 47 (03): : 181 - 181
  • [34] Role of Positron Emission Tomography- Computed Tomography in Head and Neck Cancer
    Cashman, Emma C.
    MacMahon, Peter J.
    Shelly, Martin J.
    Kavanagh, Eoin C.
    ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2011, 120 (09): : 593 - 602
  • [35] RADIOTHERAPY WITH CONCOMITANT CHEMOTHERAPY FOR HEAD AND NECK-CANCER
    VOKES, EE
    AWAN, AM
    WEICHSELBAUM, RR
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1991, 5 (04) : 753 - 767
  • [36] METAANALYSIS OF CHEMOTHERAPY IN HEAD AND NECK-CANCER - REPLY
    MUNRO, AJ
    BRITISH JOURNAL OF CANCER, 1995, 72 (04) : 1063 - 1063
  • [37] RADIOTHERAPY PLUS CHEMOTHERAPY FOR HEAD AND NECK-CANCER
    MENDENHALL, WM
    PARSONS, JT
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (08): : 579 - 580
  • [38] Comparison of Preoperative Positron Emission Tomography/Computed Tomography with Panscopy and Ultrasound in Patients with Head and Neck Cancer
    Salehi, Amir M.
    Norberg-Spaak, Lena
    Vallin, Simon
    Sgaramella, Nicola
    Nylander, Karin
    ONCOLOGY, 2020, 98 (12) : 889 - 892
  • [39] POSITION AND ROLE OF CHEMOTHERAPY IN HEAD AND NECK-CANCER
    WEIDAUER, H
    ARCHIVES OF OTO-RHINO-LARYNGOLOGY-ARCHIV FUR OHREN-NASEN-UND KEHLKOPFHEILKUNDE, 1984, 239 (02): : 104 - 105
  • [40] CHEMOTHERAPY FOR RECURRENT AND METASTATIC HEAD AND NECK-CANCER
    PINTO, HA
    JACOBS, C
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1991, 5 (04) : 667 - 686